Fractyl Health Reports Strong One-Year Data for Revita in Post-GLP-1 Weight Maintenance
GUTS has more than doubled off its 52-week low of $0.377.
Summary
Fractyl Health reported positive one-year clinical trial results for its Revita procedure, showing sustained weight maintenance after GLP-1 discontinuation, a critical development for the financially challenged biotech.
Key Events · Product Development and Regulatory · GUTS
-
Positive One-Year REVEAL-1 Results
Patients who underwent a single Revita procedure maintained approximately 78% of their GLP-1-induced weight loss at one year, with 33% continuing to lose weight.
-
Addresses Post-GLP-1 Weight Regain
The results compare favorably to published studies showing ~15% weight regain after GLP-1 withdrawal alone, highlighting Revita's potential to prevent relapse.
-
Strong Safety Profile
No procedure-related serious adverse events were observed, and mild adverse events were transient and self-limited, consistent with prior experience.
-
Future Clinical Milestones
One-year randomized data from the REMAIN-1 Midpoint Cohort is expected in Q3 2026, followed by topline six-month randomized data from the REMAIN-1 Pivotal Cohort in early Q4 2026.
Analysis · GUTS · Industrial Applications And Services
Fractyl Health, a clinical-stage company recently flagged with a 'going concern' warning, announced positive one-year results for its lead product candidate, Revita. The data shows patients maintained approximately 78% of their GLP-1-induced weight loss one year after discontinuing GLP-1 therapy and undergoing a single Revita procedure, significantly outperforming typical weight regain seen post-GLP-1 withdrawal. This strong clinical outcome for Revita, which has Breakthrough Device designation, is critical for the company's future and could attract much-needed investment or partnerships, potentially mitigating its severe financial challenges. Investors will now watch for further randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 and the REMAIN-1 Pivotal Cohort in early Q4 2026.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 50.2% of the 203 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GUTS was trading at $0.81 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $120.6M. The 52-week trading range was $0.38 to $3.03. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.